Loading…
Lobbying Spend
—
Filings
46
Firms Hired
1
Active Period
2015–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Generic Drug Issues, H.R.5376 - Build Back Better Act
Client expense: — · Firm income: $60,000
Matched citations: H.R.5376
H.R. 938- BLOCKING Act of 2019
Client expense: — · Firm income: $60,000
Matched citations: H.R. 938
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS
S. 340 - CREATES Act of 2019, Issues relating to biodefense, S. 64 - Preserve Access to Affordable Generics and Biosimilars Act
Client expense: — · Firm income: $60,000
Matched citations: S. 340
Preserve Access to Affordable Generics and Biosimilars Act
2019 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS
S. 340 - CREATES Act of 2019, Issues relating to biodefense, S. 64 - Preserve Access to Affordable Generics and Biosimilars Act
Client expense: — · Firm income: $60,000
Matched citations: S. 64
Protecting Consumer Access to Generic Drugs Act of 2019
2019 · first_quarter · Firm: FIERCE GOVERNMENT RELATIONS
H.R. 965- CREATES Act of 2019, S. 340 - CREATES Act of 2019, Issues relating to biodefense, H.R. 1499- Protecting Consumer Access to Generic Drugs Act of 2019
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1499
H.R. 965- CREATES Act of 2019, S. 340 - CREATES Act of 2019, Issues relating to biodefense, H.R. 1499- Protecting Consumer Access to Generic Drugs Act of 2019
Client expense: — · Firm income: $60,000
Matched citations: H.R. 965
A bill to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products.
2019 · first_quarter · Firm: FIERCE GOVERNMENT RELATIONS
H.R. 965- CREATES Act of 2019, S. 340 - CREATES Act of 2019, Issues relating to biodefense, H.R. 1499- Protecting Consumer Access to Generic Drugs Act of 2019
Client expense: — · Firm income: $60,000
Matched citations: S. 340
S. 974- CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, Issues relating to biodefense
Client expense: — · Firm income: $60,000
Matched citations: H.R.2212
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2018 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS
S. 974- CREATES Act of 2017, H.R.2212 - CREATES Act of 2017, Issues relating to biodefense
Client expense: — · Firm income: $60,000
Matched citations: S. 974
S. 974- CREATES Act of 2017, H.R.2212 - CREATES Act of 2017
Client expense: — · Firm income: $60,000
Matched citations: H.R.2212
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2018 · third_quarter · Firm: FIERCE GOVERNMENT RELATIONS
S. 974- CREATES Act of 2017, H.R.2212 - CREATES Act of 2017
Client expense: — · Firm income: $60,000
Matched citations: S. 974
Creating and Restoring Equal Access to Equivalent Samples Act of 2018
2018 · second_quarter · Firm: FIERCE GOVERNMENT RELATIONS
S. 974- CREATES Act of 2017
Client expense: — · Firm income: $60,000
Matched citations: S. 974
21st Century Cures Act
2016 · fourth_quarter · Firm: FIERCE GOVERNMENT RELATIONS
Issues relating to generic drugs, H.R. 34- 21st Century Cures Act
Client expense: — · Firm income: $60,000
Matched citations: H.R. 34
Source: Senate LDA